The natural compound codonolactone attenuates TGF-β1-mediated epithelial-to-mesenchymal transition and motility of breast cancer cells

Oncology Reports

Volumn 35, Issue 1, 2016, Pages 117-126

  Fu, Jianjiang ^a   Ke, Xiaoqin ^a   Tan, Songlin ^a   Liu, Ting ^a   Wang, Shan ^a   Ma, Junchao ^a   Lu, Hong ^a  

^a JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Breast cancer; Codonolactone; Epithelial to mesenchymal transition; Metastasis; TGF signaling

Indexed keywords

ANTINEOPLASTIC AGENT; BATIMASTAT; CODONOLACTONE; CYTOKERATIN 19; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NATURAL PRODUCT; NERVE CELL ADHESION MOLECULE; SMAD2 PROTEIN; SMAD3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; ATRACTYLENOLIDE III; LACTONE; SESQUITERPENE; TGFB1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANIMAL; BREAST NEOPLASMS; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LACTONES; MICE; NEOPLASM METASTASIS; SESQUITERPENES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84954055298     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4394     Document Type: Article

References (43)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014
2. Liu S, Goldstein RH, Scepansky EM and Rosenblatt M: Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res 69: 8742-8751, 2009
3. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009
4. Yilmaz M and Christofori G: EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28: 15-33, 2009
5. Son H and Moon A: Epithelial-mesenchymal transition and cell invasion. Toxicol Res 26: 245-252, 2010.
6. Gonzalez DM and Medici D: Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal 7: re8, 2014
7. Chen Q, He H, Li P, Zhu J and Xiong M: Identification and quantification of atractylenolide I and atractylenolide III in Rhizoma Atractylodes macrocephala by liquid chromatography-ion trap mass spectrometry. Biomed Chromatogr 27: 699-707, 2013.
8. Kang TH, Bang JY, Kim MH, Kang IC, Kim HM and Jeong HJ: Atractylenolide III, a sesquiterpenoid, induces apoptosis in human lung carcinoma A549 cells via mitochondria-mediated death pathway. Food Chem Toxicol 49: 514-519, 2011.
9. Zhang NN, Park DK and Park HJ: The inhibitory activity of atractylenolide III, a sesquiterpenoid, on IgE-mediated mast cell activation and passive cutaneous anaphylaxis (PCA). J Ethnopharmacol 145: 278-285, 2013.
10. Li CQ, He LC and Jin JQ: Atractylenolide I and atractylenolide III inhibit lipopolysaccharide-induced TNF-alpha and NO production in macrophages. Phytother Res 21: 347-353, 2007
11. Liu C, Zhao H, Ji ZH and Yu XY: Neuroprotection of atractylenolide III from Atractylodis macrocephalae against glutamate-induced neuronal apoptosis via inhibiting caspase signaling pathway. Neurochem Res 39: 1753-1758, 2014
12. Wang KT, Chen LG, Wu CH, Chang CC and Wang CC: Gastroprotective activity of atractylenolide III from Atractylodes ovata on ethanol-induced gastric ulcer in vitro and in vivo. J Pharm Pharmacol 62: 381-388, 2010.
13. Kang TH, Han NR, Kim HM and Jeong HJ: Blockade of IL-6 secretion pathway by the sesquiterpenoid atractylenolide III. J Nat Prod 74: 223-227, 2011.
14. Wang W, Chen B, Zou R, Tu X, Tan S, Lu H, Liu Z and Fu J: Codonolactone, a sesquiterpene lactone isolated from Chloranthus henryi Hemsl, inhibits breast cancer cell invasion, migration and metastasis by downregulating the transcriptional activity of Runx2. Int J Oncol 45: 1891-1900, 2014
15. Ferrari N, McDonald L, Morris JS, Cameron ER and Blyth K RUNX2 in mammary gland development and breast cancer. J Cell Physiol 228: 1137-1142, 2013.
16. Lee KS, Kim HJ, Li QL, Chi XZ, Ueta C, Komori T, Wozney JM, Kim EG, Choi JY, Ryoo HM, et al: Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 20: 8783-8792, 2000.
17. Phimphilai M, Zhao Z, Boules H, Roca H and Franceschi RT: BMP signaling is required for RUNX2-dependent induction of the osteoblast phenotype. J Bone Miner Res 21: 637-646, 2006.
18. Bonnomet A, Syne L, Brysse A, Feyereisen E, Thompson EW, Noël A, Foidart JM, Birembaut P, Polette M and Gilles C: A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene 31: 3741-3753, 2012.
19. Zhang Q, Yu N and Lee C: Vicious cycle of TGF-β signaling in tumor progression and metastasis. Am J Clin Exp Urol 2: 149-155, 2014
20. Borthwick LA, Gardner A, De Soyza A, Mann DA and Fisher AJ: Transforming growth factor-β1 (TGF-β1) driven epithelial to mesenchymal transition (EMT) is accentuated by tumour necrosis factor α (TNFα) via crosstalk between the SMAD and NF-KB pathways. Cancer Microenviron 5: 45-57, 2012.
21. Savagner P: The epithelial-mesenchymal transition (EMT) phenomenon. Ann Oncol 21 (Suppl 7): vii89-vii92, 2010.
22. Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15: 178-196, 2014.
23. Zeisberg M and Neilson EG: Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119: 1429-1437, 2009.
24. Angst BD, Marcozzi C and Magee AI: The cadherin superfamily: Diversity in form and function. J Cell Sci 114: 629-641, 2001.
25. Gheldof A and Berx G: Cadherins and epithelial-to-mesenchymal transition. Prog Mol Biol Transl Sci 116: 317-336, 2013.
26. Eriksson JE, Dechat T, Grin B, Helfand B, Mendez M, Pallari HM and Goldman RD: Introducing intermediate filaments: From discovery to disease. J Clin Invest 119: 1763-1771, 2009.
27. Wang Y, Shi J, Chai K, Ying X and Zhou BP: The role of Snail in EMT and tumorigenesis. Curr Cancer Drug Targets 13: 963-972, 2013.
28. Khan MA, Chen HC, Zhang D and Fu J: Twist: A molecular target in cancer therapeutics. Tumour Biol 34: 2497-2506, 2013.
29. Yang Z, Zhang X, Gang H, Li X, Li Z, Wang T, Han J, Luo T, Wen F and Wu X: Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression. Biochem Biophys Res Commun 358: 925-930, 2007.
30. Derynck R, Muthusamy BP and Saeteurn KY: Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition. Curr Opin Cell Biol 31: 56-66, 2014.
31. Thomson S, Petti F, Sujka-Kwok I, Mercado P, Bean J, Monaghan M, Seymour SL, Argast GM, Epstein DM and Haley JD: A systems view of epithelial-mesenchymal transition signaling states. Clin Exp Metastasis 28: 137-155, 2011.
32. Xu J, Lamouille S and Derynck R: TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19: 156-172, 2009.
33. Peinado H, Quintanilla M and Cano A: Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: Mechanisms for epithelial mesenchymal transitions. J Biol Chem 278: 21113-21123, 2003.
34. Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, Pietras K, Virtanen I, Philipson L, Leopold PL, et al: A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol 11: 943-950, 2009.
35. Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH and Moustakas A: HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem 283: 33437-33446, 2008.
36. Yamashita M, Fatyol K, Jin C, Wang X, Liu Z and Zhang YE: TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell 31: 918-924, 2008.
37. Xie L, Law BK, Chytil AM, Brown KA, Aakre ME and Moses HL: Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia 6: 603-610, 2004.
38. Stein GS, Lian JB, van Wijnen AJ, Stein JL, Montecino M, Javed A, Zaidi SK, Young DW, Choi JY and Pockwinse SM: Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene 23: 4315-4329, 2004.
39. Komori T: Runx2, a multifunctional transcription factor in skeletal development. J Cell Biochem 87: 1-8, 2002.
40. Inman CK and Shore P: The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 278: 48684-48689, 2003.
41. Gupta GP and Massagué J: Cancer metastasis: Building a framework. Cell 127: 679-695, 2006.
42. Chimge NO, Baniwal SK, Little GH, Chen YB, Kahn M, Tripathy D, Borok Z and Frenkel B: Regulation of breast cancer metastasis by Runx2 and estrogen signaling: The role of SNAI2. Breast Cancer Res 13: R127, 2011.
43. Niu DF, Kondo T, Nakazawa T, Oishi N, Kawasaki T, Mochizuki K, Yamane T and Katoh R: Transcription factor Runx2 is a regulator of epithelial-mesenchymal transition and invasion in thyroid carcinomas. Lab Invest 92: 1181-1190, 2012.